Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200435914> ?p ?o ?g. }
- W4200435914 endingPage "e28078" @default.
- W4200435914 startingPage "e28078" @default.
- W4200435914 abstract "Abstract Background: Combined treatment with anlotinib, irinotecan, as well as vincristine for advanced Ewing sarcoma (EWS) has been verified been effective in the prospective trial of Peking University People's Hospital EWS trial-02. We aimed to assess the dynamic changes in health-related quality of life (QoL) and the benefit-risk in quality-adjusted survival in current study. Methods: Twelve “pediatric” patients and 23 “adult” patients were enrolled. QoL was assessed with the EORTC QLQ-C30 for adults and PedsQL 3.0 Cancer Module for children and adolescents. The quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) analysis was used to describe treatment results. Results: Progression-free survival was not accompanied by diminished QoL. Differences in scores on the QoL global health status and specific functioning before, during, and after treatment were not significantly different with time ( P = .14 for adults and .91 for children). During treatment, there was a statistically insignificant trend towards improved QoL with reduced tumor burden ( P = .14 for adults and .10 for children), but QoL significantly declined with progression of disease ( P = .05 for adults and .04 for children). The most common adverse events were neutropenia (12.1%), leukopenia (16.6%), anemia (12.7%), and diarrhea (4.93%). Results across the trial analyses showed that the median time of Q-TWiST was 0.73 (interquartile range, 0–1.57) months, whereas the median time with toxicity before disease progression was 3.9 (interquartile range, 2.3, 6.1). Conclusion: QoL exhibited a trend towards improvement in accordance with high objective response in this trial with the receipt of combination therapy of anlotinib, vinsristine, and irinotecan for advanced EWS. The toxicity profile did not translate into significantly worse overall scores during treatment." @default.
- W4200435914 created "2021-12-31" @default.
- W4200435914 creator A5001749038 @default.
- W4200435914 creator A5001910335 @default.
- W4200435914 creator A5002710972 @default.
- W4200435914 creator A5005410786 @default.
- W4200435914 creator A5011450428 @default.
- W4200435914 creator A5033203853 @default.
- W4200435914 creator A5042802633 @default.
- W4200435914 creator A5050567758 @default.
- W4200435914 creator A5063848653 @default.
- W4200435914 creator A5066663062 @default.
- W4200435914 creator A5072813027 @default.
- W4200435914 creator A5080219805 @default.
- W4200435914 date "2021-12-23" @default.
- W4200435914 modified "2023-09-26" @default.
- W4200435914 title "Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine" @default.
- W4200435914 cites W127033872 @default.
- W4200435914 cites W1491888133 @default.
- W4200435914 cites W1505048261 @default.
- W4200435914 cites W1556311442 @default.
- W4200435914 cites W1566328614 @default.
- W4200435914 cites W1879554030 @default.
- W4200435914 cites W1897123512 @default.
- W4200435914 cites W1975044418 @default.
- W4200435914 cites W1977093042 @default.
- W4200435914 cites W1978440799 @default.
- W4200435914 cites W1987711531 @default.
- W4200435914 cites W1991236371 @default.
- W4200435914 cites W1994361201 @default.
- W4200435914 cites W2042936828 @default.
- W4200435914 cites W2044313879 @default.
- W4200435914 cites W2068798216 @default.
- W4200435914 cites W2072909107 @default.
- W4200435914 cites W2082075069 @default.
- W4200435914 cites W2095831811 @default.
- W4200435914 cites W2097881410 @default.
- W4200435914 cites W2103607521 @default.
- W4200435914 cites W2129318728 @default.
- W4200435914 cites W2145088312 @default.
- W4200435914 cites W2159876545 @default.
- W4200435914 cites W2160889655 @default.
- W4200435914 cites W2169775710 @default.
- W4200435914 cites W2269524163 @default.
- W4200435914 cites W2418450403 @default.
- W4200435914 cites W2528424364 @default.
- W4200435914 cites W2556328695 @default.
- W4200435914 cites W2600299187 @default.
- W4200435914 cites W2744206713 @default.
- W4200435914 cites W2759189177 @default.
- W4200435914 cites W2785885859 @default.
- W4200435914 cites W2799341684 @default.
- W4200435914 cites W2803924465 @default.
- W4200435914 cites W2804913423 @default.
- W4200435914 cites W2808043936 @default.
- W4200435914 cites W2902869461 @default.
- W4200435914 cites W2903898756 @default.
- W4200435914 cites W2906568228 @default.
- W4200435914 cites W2937017479 @default.
- W4200435914 cites W2939594976 @default.
- W4200435914 cites W3006180429 @default.
- W4200435914 cites W3016408864 @default.
- W4200435914 cites W3132817859 @default.
- W4200435914 doi "https://doi.org/10.1097/md.0000000000028078" @default.
- W4200435914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34941047" @default.
- W4200435914 hasPublicationYear "2021" @default.
- W4200435914 type Work @default.
- W4200435914 citedByCount "1" @default.
- W4200435914 countsByYear W42004359142022 @default.
- W4200435914 crossrefType "journal-article" @default.
- W4200435914 hasAuthorship W4200435914A5001749038 @default.
- W4200435914 hasAuthorship W4200435914A5001910335 @default.
- W4200435914 hasAuthorship W4200435914A5002710972 @default.
- W4200435914 hasAuthorship W4200435914A5005410786 @default.
- W4200435914 hasAuthorship W4200435914A5011450428 @default.
- W4200435914 hasAuthorship W4200435914A5033203853 @default.
- W4200435914 hasAuthorship W4200435914A5042802633 @default.
- W4200435914 hasAuthorship W4200435914A5050567758 @default.
- W4200435914 hasAuthorship W4200435914A5063848653 @default.
- W4200435914 hasAuthorship W4200435914A5066663062 @default.
- W4200435914 hasAuthorship W4200435914A5072813027 @default.
- W4200435914 hasAuthorship W4200435914A5080219805 @default.
- W4200435914 hasBestOaLocation W42004359141 @default.
- W4200435914 hasConcept C119060515 @default.
- W4200435914 hasConcept C121608353 @default.
- W4200435914 hasConcept C126322002 @default.
- W4200435914 hasConcept C141071460 @default.
- W4200435914 hasConcept C143998085 @default.
- W4200435914 hasConcept C159110408 @default.
- W4200435914 hasConcept C187212893 @default.
- W4200435914 hasConcept C197934379 @default.
- W4200435914 hasConcept C2776694085 @default.
- W4200435914 hasConcept C2776755627 @default.
- W4200435914 hasConcept C2777063308 @default.
- W4200435914 hasConcept C2778248108 @default.
- W4200435914 hasConcept C2779429289 @default.
- W4200435914 hasConcept C2779951463 @default.
- W4200435914 hasConcept C2780259306 @default.